Fundraising Fox

C2i Genomics

5 known investors

c2i-genomics.com ↗

C2i Genomics develops TrueMRD, a cancer monitoring platform that combines whole-genome sequencing with AI algorithms to build personalized tumor signatures for detecting minimal residual disease (MRD). It is aimed at oncology and clinical cancer monitoring applications.

AI & Machine LearningBiotechHealthtech

Founders & leadership

AZAsaf Zviran
Asaf ZviraninCo-Founder, CEO & CSO2019–2023Advisor at epiliquid

Investors · 5

iGlobe PartnersSingapore · $600K – $6M
LionBirdTel Aviv · $200K – $500K
NFXSan Francisco · $250K – $5M
Casdin CapitalreportedNew York
Section 32reportedPalo Alto

In the news

Cancer care startup C2i Genomics acquired by Veracyte for up to $95 million | Ctechcalcalistech.com · Jan 2024Cancer surveillance co C2i Genomics raises $100m - Globesen.globes.co.il · Apr 2021C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform -hitconsultant.net · Apr 2021C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B | TechCrunchtechcrunch.com · Apr 2021C2i Genomics raises $12M Series A funding to improve cancer patient lives and outcomes with breakthrough technology - Tech Startupstechstartups.com · Jun 2020C2i Genomics Raises $12M in Series A Funding - FinSMEsfinsmes.com · Jun 2020

Frequently asked questions

What does C2i Genomics do?
C2i Genomics develops TrueMRD, a cancer monitoring platform that combines whole-genome sequencing with AI algorithms to build personalized tumor signatures for detecting minimal residual disease (MRD). It is aimed at oncology and clinical cancer monitoring applications.
Who founded C2i Genomics?
C2i Genomics was founded by Asaf Zviran.
Who are C2i Genomics's investors?
C2i Genomics's investors include iGlobe Partners, LionBird, NFX, Casdin Capital, Section 32.